The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
May 5th 2025
KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Study: Patients With SLE, AF Experience Higher In-Hospital Mortality Rate
April 5th 2024Patients with systemic lupus erythematosus (SLE) and atrial fibrillation (AF) exhibited elevated risks of severe cardiac complications, alongside increased in-hospital mortality, costs, and length of stay (LOS).
Read More
Trends in Low-Value Cancer Care During the COVID-19 Pandemic
Among adults with newly diagnosed cancer, rates of low-value cancer services persisted throughout the COVID-19 pandemic in areas ranging from peridiagnosis imaging to end-of-life care.
Read More
Indirect Comparison Finds Bimekizumab More Effective Than Guselkumab in Psoriatic Arthritis
April 4th 2024Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor necrosis factor inhibitors.
Read More
The newest treatment approved for amyotrophic lateral sclerosis (ALS) will be withdrawn from the market due to negative clinical trial results; former President Trump’s surgeon general is advocating for conservative states to support needle exchanges; new US hepatitis C infections dropped slightly in 2022 after more than a decade of steady increases.
Read More
Dr Jonathan Silverberg Describes AD Diagnosis, Treatment in Children vs Adults
April 2nd 2024Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences, discusses atopic dermatitis (AD) diagnosis and treatment differences in children vs adults.
Watch
Children Born to Mothers With Stress, Mental Health Conditions During Pregnancy at Higher AD Risk
April 2nd 2024A meta-analysis found significant associations between maternal stress, anxiety, depression, and adverse life events during pregnancy with increased atopic dermatitis (AD) risk in offspring.
Read More
Older Patients With DLBCL Face Poor Overall Survival, High Costs With R-GemOx Treatment
April 1st 2024Treatment with R-GemOx was associated with significant health care resource utilization, high costs surrounding treatment, and low overall survival in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Read More
Medication Persistence and Its Impact on Type 2 Diabetes
Most newly treated patients with type 2 diabetes exhibit suboptimal medication persistence, which is associated with higher risk of hospitalization and increased medical costs.
Read More
Dr Raj Chovatiya Explains Oral JAK Inhibitor Monitoring Protocols for AD Treatment
April 1st 2024Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, described monitoring protocols for clinicians when using oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).
Watch
Dr Jeff Stark: Bimekizumab Shows Long-Term Efficacy When Used to Treat Patients With HS
April 1st 2024Despite the positive week 48 results when used to treat moderate to severe hidradenitis suppurativa (HS), Jeff Stark, MD, of Union Chimique Belge, noted that bimekizumab is still considered an investigational therapy for HS treatment as it has not yet received an FDA approval.
Watch
Emerging Data Continue to Evolve Treatment Utilization in MPNs
April 1st 2024Despite being used for decades, there continues to be emerging data on interferons and how they should be used in patients with myeloproliferative neoplasms (MPNs), explains Raajit Rampal, MD, PhD, hematologic oncologist, associate attending physician, Memorial Sloan Kettering Cancer Center.
Watch
Patients Treated With Mirvetuximab Soravtansine vs Chemotherapy Report Better HRQOL
March 29th 2024An abstract presented at the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer explored patient-reported health-related quality of life (HRQOL) among patients treated with mirvetuximab soravtansine compared with standard chemotherapy.
Read More